COMPARATIVE ANALYSIS AND DYNAMICS OF ECHOCG PARAMETERS IN PATIENTS WITH IHD AND T2DM WITH DIFFERENT CATEGORIES OF LVEF AT THE STAGES OF OBSERVATION

Sh.Sh. Mukhtarova; R.Kh. Trigulova; Kh.K. Nasirova; D.A. Alimova

doi:10.5281/zenodo.12192470

COMPARATIVE ANALYSIS AND DYNAMICS OF ECHOCG PARAMETERS IN PATIENTS WITH IHD AND T2DM WITH DIFFERENT CATEGORIES OF LVEF AT THE STAGES OF OBSERVATION

20.06.2024 International Scientific Journal "Science and Innovation". Series D. Volume 3 Issue 6

Sh.Sh. Mukhtarova, R.Kh. Trigulova, Kh.K. Nasirova, D.A. Alimova

Abstract. This article is devoted to assessing the relationships between EchoCG parameters and their dynamics in the ranges of preserved and moderately reduced LVEF in patients with coronary artery disease and type 2 diabetes. We examined 130 patients with type 2 diabetes and coronary artery disease with varying LVEF at the age of 65.6±9.7 years with an experience of 8.8±5.2 and 7.5±3.6 years, respectively. The results of the LVDP value between groups 2 and 3 at the outcome differed in the E/e` indicator (t==7.02, p=0.008), due to the E parameter (t==6.011, and p=0.01). At the observation stages, positive dynamics were recorded on the part of E/A in groups 2 (t==6.727, p=0.009) and 3 (t==15.830, p=0.000), E/e' (t==7.422, p=0.006 ) and (t==17.775, p=0.000) respectively. Conclusion: the identified main indicators of LVDD respond to therapy with Empagliflozin with a fairly high statistically significant power.

Keywords: diabetes mellitus type 2; cardiac ischemia; heart failure; ejection fraction; left ventricular diastolic dysfunction.

References:

1. Perepech N.B.; Mikhailova I.E. Sodium-glucose cotransporter type 2 inhibitors: successfully chasing two birds with one stone. Russian Journal of Cardiology. 2021;26(2S):4534. P.54-62 https://doi.org/10.15829/1560-4071-2021-4534 2. Yuryeva M.Yu.; Dvoryashina I.V. The significance of hyperglycemia and glycemic variability in patients with decompensated chronic heart failure depending on the severity of carbohydrate metabolism disorders // Cardiology. - 2017. - T. 57. - No. S4. - P.38-46. https://doi.org/10.18087/cardio.2403 3. Ather S; Chan W; Bozkurt B; et al. Impact of Noncardiac Comorbidities on Morbidity and Mortality in a Predominantly Male Population with Heart Failure and Preserved versus Reduced Ejection Fraction. J Am Coll Cardiol. 2012;59(11):998-1005. https://doi.org/10.1016/j.jacc.2011.11.040 4. Galiero R; Caturano A; Vetrano E; Monda M; Marfella R; Sardu C; Salvatore T; Rinaldi L; Sasso FC. Precision Medicine in Type 2 Diabetes Mellitus: Utility and Limitations. Diabetes Metab Syndr Obes. 2023 Nov 16;16: 3669-3689. https:// doi.org/10.2147/DMSO.S390752 5. Jensen J; Omar M; Kistorp C. Et al. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF). Trials. 2019 Jun 21;20(1):374. https:// doi.org/10.1186/s13063-019-3474-5 6. https://www.mdcalc.com/calc/10105/h2fpef-score-for-heart-failure-with-preserved-ejection-fraction. Reddy YNV; Carter RE; Obokata M; Redfield MM; Borlaug BA. A Simple; Evidence-Based Approach to Help Guide Diagnosis of Heart Failure with Preserved Ejection Fraction. Circulation. 2018;138(9):861– 70. DOI: 10.1161/CIRCULATIONAHA.118.034646 7. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. 2016 Apr;29(4):277-314. doi: 10.1016/j.echo.2016.01.011.